Tecan employees and partners around the world have made it possible for us to achieve another strong financial performance in the first half of this year. We are particularly pleased with the strong double-digit growth in applications that are not related to the COVID pandemic. It exceeds our earlier expectations that we were able to deliver organic sales growth in our Life Sciences Business segment already in the first half of the year, despite the extraordinarily high base from the prior-year period. This strong performance is based on high demand for our automation solutions in all major geographies, covering multiple customer segments and end applications. The Partnering Business also saw strong revenue growth for our Cavro components and experienced an upswing in demand for non-Covid routine diagnostic applications. The integration of Paramit is progressing well and the newly consolidated business delivered solid sales growth in line with expectations. Based on the positive business performance and momentum in the first six months, we are raising our revenue outlook for the full-year 2022.

Sales of CHF 584.0 million (H1 2021: CHF 454.0 million)

  • Growth of +28.6% in Swiss francs or +29.0% in local currencies
  • Strong growth of organic non-COVID-related sales, estimated in the mid-teens percentage range, helped to largely offset substantial decline in COVID-related revenues recorded in prior-year period
  • Organic sales decline of only -4.3% in local currencies, against a high COVID-driven comparison base of +47.5% growth in the prior-year period
  • Life Sciences Business segments achieved organic growth of +4.3% in local currencies based on strong global demand for automation solutions

Adjusted EBITDA of CHF 119.1 million (H1 2021: CHF 115.0 million)

  • Adjusted EBITDA margin of 20.4%, excluding Paramit of 22.1% (H1 2021: 25.3%)

Outlook for full-year sales growth raised, now forecasted to be in the mid- to high-teens percentage range in local currencies